Related Experiment Video
Updated: May 24, 2026

Comparing the Affinity of GTPase-binding Proteins using Competition Assays
Published on: October 8, 2015
Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase
Brenda L Montalvo-Ortiz1, Linette Castillo-Pichardo, Eliud Hernández
1Department of Biochemistry, School of Medicine, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico.
Abstract:
The Rho GTPase Rac regulates actin cytoskeleton reorganization to form cell surface extensions (lamellipodia) required for cell migration/invasion during cancer metastasis. Rac hyperactivation and overexpression are associated with aggressive cancers; thus, interference of the interaction of Rac with its direct upstream activators, guanine nucleotide exchange factors (GEFs), is a viable strategy for inhibiting Rac activity. We synthesized EHop-016, a novel inhibitor of Rac activity, based on the structure of the established Rac/Rac GEF inhibitor NSC23766. Herein, we demonstrate that EHop-016 inhibits Rac activity in the MDA-MB-435 metastatic cancer cells that overexpress Rac and exhibits high endogenous Rac activity. The IC(50) of 1.1 μM for Rac inhibition by EHop-016 is ∼100-fold lower than for NSC23766. EHop-016 is specific for Rac1 and Rac3 at concentrations of ≤5 μM. At higher concentrations, EHop-016 inhibits the close homolog Cdc42. In MDA-MB-435 cells that demonstrate high active levels of the Rac GEF Vav2, EHop-016 inhibits the association of Vav2 with a nucleotide-free Rac1(G15A), which has a high affinity for activated GEFs. EHop-016 also inhibits the Rac activity of MDA-MB-231 metastatic breast cancer cells and reduces Rac-directed lamellipodia formation in both cell lines. EHop-016 decreases Rac downstream effects of PAK1 (p21-activated kinase 1) activity and directed migration of metastatic cancer cells. Moreover, at effective concentrations (<5 μM), EHop-016 does not affect the viability of transformed mammary epithelial cells (MCF-10A) and reduces viability of MDA-MB-435 cells by only 20%. Therefore, EHop-016 holds promise as a targeted therapeutic agent for the treatment of metastatic cancers with high Rac activity.
Insights
A novel inhibitor, EHop-016, effectively targets hyperactive Rho GTPase Rac in metastatic cancer cells. This compound shows promise for treating aggressive cancers by inhibiting Rac activity and cell migration with minimal impact on normal cell viability.
Area of Science:
- Molecular biology
- Cancer research
- Drug discovery
Background:
- The Rho GTPase Rac is crucial for cell migration and invasion in cancer metastasis, with its hyperactivation linked to aggressive disease.
- Targeting the interaction between Rac and its activators (guanine nucleotide exchange factors) is a potential therapeutic strategy.
Purpose of the Study:
- To synthesize and evaluate EHop-016, a novel inhibitor of Rac activity, for its potential as a targeted therapeutic agent in metastatic cancers.
- To assess the efficacy and specificity of EHop-016 in inhibiting Rac activity and downstream effects in relevant cancer cell models.
Main Methods:
- Synthesis of EHop-016, a novel Rac/Rac GEF inhibitor.
- Inhibition assays in MDA-MB-435 and MDA-MB-231 metastatic cancer cell lines.
- Assessment of Rac activity, GEF-Rac interaction, lamellipodia formation, PAK1 activity, cell migration, and cell viability.
Main Results:
- EHop-016 potently inhibits Rac activity (IC50 = 1.1 μM) in MDA-MB-435 cells, approximately 100-fold more effectively than NSC23766.
- EHop-016 demonstrates specificity for Rac1 and Rac3 at concentrations ≤5 μM and inhibits Vav2-Rac1 interaction.
- EHop-016 reduces lamellipodia formation, PAK1 activity, and migration in metastatic cancer cells, with minimal toxicity to normal cells.
Conclusions:
- EHop-016 is a potent and specific inhibitor of Rac activity with significant potential for treating metastatic cancers.
- The compound effectively targets key pathways involved in cancer cell migration and invasion, offering a promising therapeutic avenue.
More Related Videos
10:27Spatio-Temporal Manipulation of Small GTPase Activity at Subcellular Level and on Timescale of Seconds in Living Cells
Published on: March 9, 2012
13:51Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay
Published on: November 11, 2018
Related Concept Videos
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
GTPases and their Regulation
Large G-proteins, also known...
GTPases and their Regulation
Large G-proteins, also known...
Cell Polarization by Rho Proteins
Rab Proteins
Rab proteins switch between a cytosolic, GDP-bound inactive state and a membrane-anchored, GTP-bound active state. By themselves, Rabs show slow rates of GDP/GTP exchange and GTP hydrolysis. Thus, Rab proteins are considered...
Activation and Inactivation of G Proteins